Background Background Most evidence
Most evidence suggesting an association between suggesting an association between schizophrenia, antipsychotic medications schizophrenia, antipsychotic medications and diabetes has been based on and diabetes has been based on retrospective studies not controlled for retrospective studies not controlled for important confounders. important confounders.
Aims Aims To compare diabetogenic risk
To compare diabetogenic risk between antipsychotic medications; and between antipsychotic medications; and to describe the limitations of current to describe the limitations of current prospective data-sets. prospective data-sets.
Method Method Systematic review of
Systematic review of prospective clinical data. prospective clinical data.
Results

Results No difference in the incidence
No difference in the incidence of glycaemic abnormalities between of glycaemic abnormalities between placebo cohorts and antipsychotic placebo cohorts and antipsychotic medication cohorts was identified.No medication cohorts was identified.No significant difference between any of the significant difference between any of the antipsychotic medications studied in terms antipsychotic medications studied in terms of their association with glycaemic of their association with glycaemic abnormalities was identified.Treatmentabnormalities was identified.Treatmentrelated weight gain did not appear to related weight gain did not appear to increase the risk of developing diabetes. increase the riskof developing diabetes.
Conclusions Conclusions Diabetogenic potential
Diabetogenic potential ascribed to atypical antipsychotic drugs, ascribed to atypical antipsychotic drugs, resulting from retrospective studies, may resulting from retrospective studies, may be incorrect. Cohort sizes and incomplete be incorrect. Cohort sizes and incomplete sampling must preclude any definitive sampling must preclude any definitive conclusions.Long-term, large, conclusions.Long-term, large, comparative prospective trials are comparative prospective trials are needed, along with agreement upon needed, along with agreement upon glucose measurement of choice. glucose measurement of choice. schizophrenia.
Declaration of interest
Despite almost a century of acknowledgeDespite almost a century of acknowledgement that an association exists between ment that an association exists between schizophrenia and type 2 diabetes, most of schizophrenia and type 2 diabetes, most of the available evidence is retrospective in the available evidence is retrospective in nature. The limitations of such retrospective nature. The limitations of such retrospective data in confirming causality between any data in confirming causality between any drug and any illness are well recognised. In drug and any illness are well recognised. In the past 2 years several major retrospective the past 2 years several major retrospective studies have been published, which have studies have been published, which have evaluated large databases of over 150 000 evaluated large databases of over 150 000 patients in an effort to define the exact patients in an effort to define the exact nature of the relationship between antinature of the relationship between antipsychotic medications and type 2 diabetes psychotic medications and type 2 diabetes (Kornegay (Kornegay et al et al, 2002; Koro , 2002; Koro et al et al, 2002; , 2002; Sernyak Sernyak et al et al, 2002; Buse , 2002; Buse et al et al, 2003; , 2003; Cunningham Cunningham et al et al, 2003) . Unfortunately, , 2003) . Unfortunately, no study has been able to control for all no study has been able to control for all important confounders, such body mass important confounders, such body mass index, gender, family history of diabetes, index, gender, family history of diabetes, levels of screening for blood glucose levels of screening for blood glucose abnormalities, severity of psychosis and abnormalities, severity of psychosis and diagnostic accuracy. This severely weakens diagnostic accuracy. This severely weakens the evidence and makes it hard to draw the evidence and makes it hard to draw valid conclusions. valid conclusions.
The precise definition of exactly how The precise definition of exactly how diabetes has been diagnosed in these studies diabetes has been diagnosed in these studies is also unknown. The limitations of meais also unknown. The limitations of measures of fasting and random blood glucose sures of fasting and random blood glucose levels in terms of sensitivity of diagnosis levels in terms of sensitivity of diagnosis are now well recognised, and may be exacerare now well recognised, and may be exacerbated by the difficulties of obtaining blood bated by the difficulties of obtaining blood samples from people with schizophrenia. samples from people with schizophrenia. None of the above studies specifies how None of the above studies specifies how many patients received a diagnosis of diamany patients received a diagnosis of diabetes based on an oral glucose tolerance test betes based on an oral glucose tolerance test (currently regarded as the gold standard). (currently regarded as the gold standard).
METHOD METHOD
A systematic review was made of publicly A systematic review was made of publicly available prospective clinical data, focusing available prospective clinical data, focusing mainly on studies with placebo cohorts. mainly on studies with placebo cohorts.
RESULTS RESULTS
Establishing true prevalence rates Establishing true prevalence rates
Recent cross-sectional epidemiological Recent cross-sectional epidemiological studies have clearly demonstrated that in studies have clearly demonstrated that in order to establish true prevalence figures order to establish true prevalence figures for both type 2 diabetes and impaired glufor both type 2 diabetes and impaired glucose tolerance, it is essential to undertake cose tolerance, it is essential to undertake some form of blood glucose testing to consome form of blood glucose testing to confirm the diagnosis (Cohn firm the diagnosis (Cohn et al et al, 2002; Ryan , 2002; Ryan et al et al, 2003; Subramaniam , 2003; Subramaniam et al et al, 2003) . , 2003) . None of the retrospective epidemiological None of the retrospective epidemiological studies conducted to date reported the studies conducted to date reported the numbers of patients within each cohort numbers of patients within each cohort who had been actively screened for blood who had been actively screened for blood glucose abnormalities, and some studies glucose abnormalities, and some studies (Buse (Buse et al et al, 2003; Cunningham , 2003; Cunningham et al et al, , 2003) (2003) provide uncompromising evidence for the importance compromising evidence for the importance of blood glucose screening when attempting of blood glucose screening when attempting to establish the prevalence of diabetes and to establish the prevalence of diabetes and impaired glucose tolerance. These investiimpaired glucose tolerance. These investigators undertook a chart review of 607 gators undertook a chart review of 607 patients with chronic schizophrenia (all patients with chronic schizophrenia (all receiving typical antipsychotic medication receiving typical antipsychotic medication such as chlorpromazine and haloperidol), such as chlorpromazine and haloperidol), and found a prevalence of type 2 diabetes and found a prevalence of type 2 diabetes of 4.9%. Patients known to have diabetes of 4.9%. Patients known to have diabetes were then excluded from any further analywere then excluded from any further analysis in this study. After informed consent sis in this study. After informed consent was given by 194 of the remaining patients, was given by 194 of the remaining patients, a fasting blood glucose level was assessed a fasting blood glucose level was assessed and an oral glucose tolerance test (OGTT) and an oral glucose tolerance test (OGTT) was performed. The prevalence of prewas performed. The prevalence of previously unrecognised type 2 diabetes was viously unrecognised type 2 diabetes was found to be 16%, taking the true prevafound to be 16%, taking the true prevalence rate in the study population to around lence rate in the study population to around 21%. A further 31% of patients were found 21%. A further 31% of patients were found to have impaired glucose tolerance. Comto have impaired glucose tolerance. Comparative prevalence figures in the general parative prevalence figures in the general population are reported to be 1.2-6.3% population are reported to be 1.2-6.3% for diabetes and 5.2-11.8% for impaired for diabetes and 5.2-11.8% for impaired glucose tolerance (Gourdy glucose tolerance (Gourdy et al et al, 2001; , 2001; Ryan Ryan et al et al, 2003) , the latter data being , 2003), the latter data being age-adjusted (35-64 years) data from a age-adjusted (35-64 years) data from a relatively recent study (1995) (1996) (1997) in relatively recent study (1995) (1996) (1997) (2003) has highlighted an equally important issue of differential equally important issue of differential screening within patient populations when screening within patient populations when patients take different antipsychotic medipatients take different antipsychotic medications. In his retrospective epidemiological cations. In his retrospective epidemiological study conducted in New York, Citrome study conducted in New York, Citrome found that patients with schizophrenia found that patients with schizophrenia taking clozapine were far more likely to taking clozapine were far more likely to have been prospectively screened for blood have been prospectively screened for blood glucose abnormalities than comparator glucose abnormalities than comparator populations, which calls into question populations, which calls into question the apparent finding that clozapine is the apparent finding that clozapine is associated with the greatest risk of diabetes associated with the greatest risk of diabetes of all the atypical antipsychotic agents. of all the atypical antipsychotic agents.
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
These data-sets suggest that many psyThese data-sets suggest that many psychiatrists who do not routinely screen their chiatrists who do not routinely screen their patients with schizophrenia using some patients with schizophrenia using some form of blood glucose testing will fail to form of blood glucose testing will fail to diagnose most cases of diabetes. Moreover, diagnose most cases of diabetes. Moreover, without prospective screening for glycaemic without prospective screening for glycaemic abnormalities, almost all cases of impaired abnormalities, almost all cases of impaired glucose tolerance will be overlooked. glucose tolerance will be overlooked. Because it is highly likely that a significant Because it is highly likely that a significant proportion of these patients will develop proportion of these patients will develop type 2 diabetes within a few years (Alberti, type 2 diabetes within a few years (Alberti, 1996) , lack of routine blood glucose screen-1996), lack of routine blood glucose screening in this population is a matter of grave ing in this population is a matter of grave concern. concern.
Confounding variables Confounding variables
Family history Family history
A positive family history of diabetes should A positive family history of diabetes should be considered a major confounder in epibe considered a major confounder in epidemiological studies of patients with demiological studies of patients with schizophrenia, because 17-30% of people schizophrenia, because 17-30% of people with schizophrenia have family members with schizophrenia have family members with a diagnosis of type 2 diabetes (Dynes, with a diagnosis of type 2 diabetes (Dynes, 1969; Mukherjee 1969; Mukherjee et al et al, 1989; Cheta , 1989; Cheta et al et al, , 1990; Lamberti 1990; Lamberti et al et al, 2003) . , 2003) . The importance of a positive family The importance of a positive family history of diabetes was demonstrated most history of diabetes was demonstrated most clearly in the recent cross-sectional prevaclearly in the recent cross-sectional prevalence study by Lamberti lence study by Lamberti et al et al (2003) . It (2003) . It was found that the cohort of patients with was found that the cohort of patients with schizophrenia who did not have a family schizophrenia who did not have a family history of diabetes had a prevalence of history of diabetes had a prevalence of type 2 diabetes of just 10%, whereas the type 2 diabetes of just 10%, whereas the cohort with a positive family history had cohort with a positive family history had a prevalence of 33%. a prevalence of 33%.
Psychosis Psychosis
Although severity of psychosis may repreAlthough severity of psychosis may represent a true independent risk factor for type sent a true independent risk factor for type 2 diabetes, there is an additional potential 2 diabetes, there is an additional potential confounder in that psychotic stress appears confounder in that psychotic stress appears to lead to transient and reversible changes to lead to transient and reversible changes in glucose and insulin levels, and in parain glucose and insulin levels, and in parameters of insulin resistance (Shiloah meters of insulin resistance (Shiloah et al et al, , 2003) .
2003).
Importance of an appropriate Importance of an appropriate placebo group placebo group
Design difficulties encountered with retroDesign difficulties encountered with retrospective database analyses are further comspective database analyses are further compounded because it is almost impossible to pounded because it is almost impossible to obtain a valid placebo group for comparaobtain a valid placebo group for comparative purposes. Use of the general population tive purposes. Use of the general population as a 'placebo' group is far from ideal when as a 'placebo' group is far from ideal when assessing the impact of antipsychotic assessing the impact of antipsychotic medications on the development of type 2 medications on the development of type 2 diabetes because of the inherently higher diabetes because of the inherently higher risk of glycaemic abnormalities associated risk of glycaemic abnormalities associated with schizophrenia. with schizophrenia.
Developments in knowledge about the Developments in knowledge about the clinical course and outcome of schizoclinical course and outcome of schizophrenia have made it unethical to conduct phrenia have made it unethical to conduct placebo-controlled studies in normal placebo-controlled studies in normal circumstances. Lieberman circumstances. Lieberman et al et al (2003 Lieberman et al et al ( ) (2003 found that in a prospective randomised found that in a prospective randomised controlled trial (RCT) with first-episode controlled trial (RCT) with first-episode patients given either chlorpromazine or patients given either chlorpromazine or clozapine, longer duration of untreated psyclozapine, longer duration of untreated psychosis was associated with lower odds of chosis was associated with lower odds of achieving remission. Even in studies that achieving remission. Even in studies that included a placebo group, the protocol included a placebo group, the protocol design is such that the placebo cohorts design is such that the placebo cohorts are much smaller than the comparator are much smaller than the comparator groups (Meehan groups (Meehan et al et al, 2001; Wright , 2001; Wright et al et al, , 2001 ).
2001).
Several recent studies assessing novel Several recent studies assessing novel molecules in the treatment of schizophrenia molecules in the treatment of schizophrenia have, nevertheless, been able to use placebo have, nevertheless, been able to use placebo groups (Rein & Arvantis, 2003) . Although groups (Rein & Arvantis, 2003) . Although small, these placebo groups can provide small, these placebo groups can provide valuable data on blood glucose levels prior valuable data on blood glucose levels prior to antipsychotic drug administration. The to antipsychotic drug administration. The Food and Drug Administration (2003) and Food and Drug Administration (2003) and Sowell Sowell et al et al (2003) give other examples of (2003) give other examples of data-sets that include placebo cohorts from data-sets that include placebo cohorts from prospective placebo-controlled studies such prospective placebo-controlled studies such as those relating to aripiprazole. as those relating to aripiprazole.
Diabetologists emphasise that even Diabetologists emphasise that even with intensive blood glucose monitoring with intensive blood glucose monitoring and the use of effective treatment regimens, and the use of effective treatment regimens, the typical pattern in type 2 diabetes is a the typical pattern in type 2 diabetes is a gradual worsening of glucose homoeostagradual worsening of glucose homoeostasis. Data are available from diabetes studies sis. Data are available from diabetes studies in the general population and from schizoin the general population and from schizophrenia clinical trials that support the conphrenia clinical trials that support the concept of expecting a gradual worsening in cept of expecting a gradual worsening in glucose tolerance (Wang glucose tolerance (Wang et al et al, 2003; UK , 2003 ; UK Prospective Diabetes Study Group, 1995 , Prospective Diabetes Study Group, 1995 , 1998 . The UK Prospective Diabetes Study 1998). The UK Prospective Diabetes Study (the largest and longest diabetes study ever (the largest and longest diabetes study ever performed in patients with type 2 diabetes) performed in patients with type 2 diabetes) found that traditional oral monotherapy found that traditional oral monotherapy agents (metformin and the sulphonylureas) agents (metformin and the sulphonylureas) failed to maintain long-term blood glucose failed to maintain long-term blood glucose control (UK Prospective Diabetes Study control (UK Prospective Diabetes Study Group, 1995) . After 3 years of treatment, Group, 1995) . After 3 years of treatment, half of the patients needed combination half of the patients needed combination therapy, and after 4 years, glycosylated therapy, and after 4 years, glycosylated haemoglobin (HbA haemoglobin (HbA 1c 1c ) concentrations had ) concentrations had risen to above pre-treatment levels. Data risen to above pre-treatment levels. Data from the same study in 1998 showed from the same study in 1998 showed similar findings (UK Prospective Diabetes similar findings (UK Prospective Diabetes Study Group, 1998) . Study Group, 1998) .
Data from prospective RCTs in patients Data from prospective RCTs in patients with schizophrenia also confirm that a with schizophrenia also confirm that a deterioration in glucose control is a comdeterioration in glucose control is a common and consistent finding, and unrelated mon and consistent finding, and unrelated to individual treatments (Wang to individual treatments (Wang et al et al, , 2003) . Over the course of a series of clinical 2003). Over the course of a series of clinical trials involving olanzapine, haloperidol and trials involving olanzapine, haloperidol and valproate (with an average duration of 7 valproate (with an average duration of 7 months), 22% (15/69) of patients with months), 22% (15/69) of patients with schizophrenia and 32% (6/19) of patients schizophrenia and 32% (6/19) of patients with bipolar disorder needed an increase with bipolar disorder needed an increase in their antidiabetic medications, which is in their antidiabetic medications, which is consistent with historical data in people consistent with historical data in people without mental illness. without mental illness.
Placebo cohorts in such schizophrenia Placebo cohorts in such schizophrenia studies allow prospective evaluations to be studies allow prospective evaluations to be made using preplanned blood glucose testmade using preplanned blood glucose testing. In essence, what can be measured in ing. In essence, what can be measured in these medication-free cohorts represents these medication-free cohorts represents the natural progression of both diabetes the natural progression of both diabetes and schizophrenia, combined with the and schizophrenia, combined with the impact of lifestyle risk factors such as poor impact of lifestyle risk factors such as poor diet, smoking and lack of exercise. These diet, smoking and lack of exercise. These risk factors are well recognised in the risk factors are well recognised in the schizophrenia population. schizophrenia population.
Prospective data collection Prospective data collection
Value of prospective data collection Value of prospective data collection
The value of data collected from prospecThe value of data collected from prospective RCTs, where most recognised confountive RCTs, where most recognised confounders can be eliminated, is clear. Patients ders can be eliminated, is clear. Patients entering a prospective schizophrenia study entering a prospective schizophrenia study are, by necessity, screened for glycaemic are, by necessity, screened for glycaemic abnormalities prior to study entry, and abnormalities prior to study entry, and those with abnormal levels of blood glucose those with abnormal levels of blood glucose are generally excluded. Randomisation are generally excluded. Randomisation minimises the effects of potential confounminimises the effects of potential confounders and reduces bias. True incidence figders and reduces bias. True incidence figures for both type 2 diabetes and impaired ures for both type 2 diabetes and impaired glucose tolerance in a particular trial can glucose tolerance in a particular trial can thus be established, allowing robust comthus be established, allowing robust comparisons to be made between individual parisons to be made between individual antipsychotic medications, and offering antipsychotic medications, and offering the potential to rank all antipsychotic the potential to rank all antipsychotic s 8 8 s 8 8 medications in terms of their diabetogenic medications in terms of their diabetogenic potential. potential.
Potential limitations Potential limitations
Clinical trials should recruit appropriately Clinical trials should recruit appropriately sized cohorts in order to reduce the likelisized cohorts in order to reduce the likelihood of spurious results. When possible, hood of spurious results. When possible, there should be clear agreement as to the there should be clear agreement as to the major parameters to be evaluated. Groups major parameters to be evaluated. Groups chosen should be demographically similar chosen should be demographically similar to each other and representative of the to each other and representative of the population to be studied. population to be studied.
A specific limitation of blood glucose A specific limitation of blood glucose level evaluation in prospective studies is level evaluation in prospective studies is lack of agreement on the most appropriate lack of agreement on the most appropriate tests to be used and the specific time points tests to be used and the specific time points that create relevance to the long-term treatthat create relevance to the long-term treatment of patients with schizophrenia. Where ment of patients with schizophrenia. Where this becomes apparent in schizophrenia this becomes apparent in schizophrenia trials is the difficulty in obtaining fasting trials is the difficulty in obtaining fasting blood glucose levels. Very little information blood glucose levels. Very little information is currently available about the prospective is currently available about the prospective use of OGTTs. use of OGTTs.
Comparisons of antipsychotics Comparisons of antipsychotics with placebo with placebo
A number of prospective placebo-A number of prospective placebocontrolled RCTs are reported either singly controlled RCTs are reported either singly or in combination on the Food and Drug or in combination on the Food and Drug Administration (FDA) website (Food and Administration (FDA) website (Food and Drug Administration, 2003) , and form part Drug Administration, 2003), and form part of the data submitted to support the safety of the data submitted to support the safety evaluations of aripiprazole by the FDA. evaluations of aripiprazole by the FDA. Five double-masked RCTs are reported, Five double-masked RCTs are reported, comparing 416 placebo-treated patients comparing 416 placebo-treated patients and 932 aripiprazole-treated patients. In and 932 aripiprazole-treated patients. In general, the short-term studies performed general, the short-term studies performed with aripiprazole were 4 weeks in duration with aripiprazole were 4 weeks in duration and used dosages of 10-30 mg a day and used dosages of 10-30 mg a day (Marder (Marder et al et al, 2003) ; one of them (study , 2003) ; one of them (study 5) lasted 6 weeks. Unfortunately, because 5) lasted 6 weeks. Unfortunately, because of the way the data are presented, it is not of the way the data are presented, it is not always possible to identify the individual always possible to identify the individual study being referred to. However, all the study being referred to. However, all the blood glucose data available from the aripiblood glucose data available from the aripiprazole studies with placebo comparators prazole studies with placebo comparators are summarised in Table 1 . are summarised in Table 1 .
Fasting blood glucose levels are reFasting blood glucose levels are reported from only one RCT (Marder ported from only one RCT (Marder et al et al, , 2003) . The remainder of the glucose data 2003). The remainder of the glucose data is limited to random blood glucose levels. is limited to random blood glucose levels. Fasting blood glucose data from one Fasting blood glucose data from one short-term RCT comparing aripiprazole short-term RCT comparing aripiprazole and placebo show similar rates of glucose and placebo show similar rates of glucose abnormalities (defined as a treatmentabnormalities (defined as a treatmentemergent glucose level that rose to above emergent glucose level that rose to above normal limits) in the placebo group normal limits) in the placebo group (10%, 3/29) and the aripiprazole group (10%, 3/29) and the aripiprazole group (6%; 6/109). The data appear to derive (6%; 6/109). The data appear to derive from a partial selection of patients particifrom a partial selection of patients participating in the only 6-week study (study 5) pating in the only 6-week study (study 5) in which fasting blood glucose data were in which fasting blood glucose data were collected on 'a limited number of patients' collected on 'a limited number of patients' (Marder (Marder et al et al, 2003) . No demographic data , 2003) . No demographic data were given for the chosen population, and were given for the chosen population, and no explanation was offered about the no explanation was offered about the choice of patients to include. From the choice of patients to include. From the original 420 patients randomised to receive original 420 patients randomised to receive various doses of aripiprazole (10 mg, 15 mg various doses of aripiprazole (10 mg, 15 mg or 20 mg) or placebo, fasting blood glucose or 20 mg) or placebo, fasting blood glucose levels are reported for 138 patients (33%). levels are reported for 138 patients (33%). This equates to tests on only 27% of the This equates to tests on only 27% of the placebo cohorts and 35% of the patients placebo cohorts and 35% of the patients given aripiprazole. From almost the same given aripiprazole. From almost the same cohort, mean fasting blood glucose levels cohort, mean fasting blood glucose levels showed similar changes from baseline showed similar changes from baseline for the aripiprazole ( for the aripiprazole (À0.37 mg/dl 0.37 mg/dl (0.021 mmol/l); (0.021 mmol/l); n n¼120) and placebo 120) and placebo groups ( groups (À5.03 mg/dl (0.279 mmol/l); 5.03 mg/dl (0.279 mmol/l); n n¼34). It is not clear at which time points 34). It is not clear at which time points the glucose measurements were taken in the glucose measurements were taken in this study, although in study 3 blood this study, although in study 3 blood samples were collected at baseline and on samples were collected at baseline and on days 14 and 28 (Kane days 14 and 28 (Kane et al et al, 2002; Marder , 2002; Marder et al et al, 2003 Marder et al et al, ). , 2003 . Random blood glucose test data are Random blood glucose test data are also reported from these five short-term also reported from these five short-term RCTs, with abnormalities reported in 9 of RCTs, with abnormalities reported in 9 of 648 (1.4%) patients taking aripiprazole 648 (1.4%) patients taking aripiprazole and 4 of 309 (1.3%) participants given and 4 of 309 (1.3%) participants given the placebo. Abnormal glucose level was the placebo. Abnormal glucose level was defined as an increase during the study defined as an increase during the study from an initial value of from an initial value of 5 5160 mg/dl 160 mg/dl (8.8 mmol/l) (considered a normal baseline (8.8 mmol/l) (considered a normal baseline value) to value) to 4 4200 mg/dl (11.1 mmol/l) 200 mg/dl (11.1 mmol/l) (Marder (Marder et al et al, 2003) . No information is , 2003) . No information is given to explain why random glucose testgiven to explain why random glucose testing data were unavailable for the remaining ing data were unavailable for the remaining members of the aripiprazole and placebo members of the aripiprazole and placebo cohorts, or how the cohorts were selected. cohorts, or how the cohorts were selected. Demographic data for included and Demographic data for included and excluded patients are also missing. excluded patients are also missing. (2003) report (2003) report that 932 patients were originally randomthat 932 patients were originally randomised to treatment with aripiprazole, and ised to treatment with aripiprazole, and it is unclear why this figure falls to 926 it is unclear why this figure falls to 926 patients later in the paper. patients later in the paper.
Although several different definitions Although several different definitions for glucose abnormalities are used in this for glucose abnormalities are used in this data-set, a clear trend emerges that whatdata-set, a clear trend emerges that whatever comparison is made, there appears ever comparison is made, there appears to be no significant difference between to be no significant difference between treatment with aripiprazole and placebo. treatment with aripiprazole and placebo. Despite limitations associated with the Despite limitations associated with the placebo data from these studies (i.e. placebo data from these studies (i.e. follow-up was short and individual study follow-up was short and individual study cohorts were small), the incidence of cohorts were small), the incidence of glucose abnormalities seen in the placebo glucose abnormalities seen in the placebo groups was similar to that reported with groups was similar to that reported with each antipsychotic medication. each antipsychotic medication. . Each study or series defined 'glucose abnormality' in a different way, 'glucose abnormality' in a different way, and the use of random blood glucose samand the use of random blood glucose samples in some studies suggests that fasting ples in some studies suggests that fasting blood glucose tests were not always feasible blood glucose tests were not always feasible in these patients. Single random blood in these patients. Single random blood glucose tests, in the absence of symptoms glucose tests, in the absence of symptoms of hyperglycaemia, are not recommended of hyperglycaemia, are not recommended by the American Diabetes Association by the American Diabetes Association (1977), the World Health Organization (1977), the World Health Organization (1999) or Diabetes UK for diagnostic (1999) or Diabetes UK for diagnostic purposes, and HbA purposes, and HbA 1c 1c levels were not availlevels were not available in any of these study groups. Sowell able in any of these study groups. Sowell s 8 9 s 8 9 (Table 2) . They reported an overall inci- (Table 2) . They reported an overall incidence rate of glucose abnormalities of dence rate of glucose abnormalities of 1.9% for the whole group, which is similar 1.9% for the whole group, which is similar to the rate reported by Citrome (2003) (2003) found an incidence of abnormally high blood glucose incidence of abnormally high blood glucose levels of 14% (14/101) in a follow-up levels of 14% (14/101) in a follow-up period of only 14 weeks (Table 2 ). Fasting period of only 14 weeks (Table 2) . Fasting blood glucose levels greater than blood glucose levels greater than 6.9 mmol/l were used as the standard 6.9 mmol/l were used as the standard definition of diabetes, and patients with definition of diabetes, and patients with existing diabetes were excluded from the existing diabetes were excluded from the study. The exceptionally high incidence study. The exceptionally high incidence of glycaemic abnormalities seen in this of glycaemic abnormalities seen in this study can be partly explained by the study can be partly explained by the nature of the study population (i.e. nature of the study population (i.e. patients with treatment-resistant schizopatients with treatment-resistant schizophrenia) and the high medication dosages phrenia) and the high medication dosages used. The rates of blood glucose abnormused. The rates of blood glucose abnormalities observed were, however, equally alities observed were, however, equally distributed between the individual cohorts distributed between the individual cohorts of patients receiving olanzapine, risperiof patients receiving olanzapine, risperidone or clozapine. done or clozapine.
Comparisons between Comparisons between antipsychotic drugs antipsychotic drugs
The FDA website contains currently The FDA website contains currently unpublished data from a 26-week study unpublished data from a 26-week study comparing aripiprazole and olanzapine comparing aripiprazole and olanzapine (Food and Drug Administration, 2003) . (Food and Drug Administration, 2003) . Rates of glycaemic abnormalities reported Rates of glycaemic abnormalities reported were similar in the aripiprazole (4.7%) were similar in the aripiprazole (4.7%) and olanzapine (4.5%) cohorts (Table 2) . and olanzapine (4.5%) cohorts (Table 2) . No association was found between weight No association was found between weight gain and blood glucose abnormalities. gain and blood glucose abnormalities. Indeed, over the 6-month study period, Indeed, over the 6-month study period, patients treated with olanzapine gained a patients treated with olanzapine gained a mean of 3.6 kg, whereas those receiving mean of 3.6 kg, whereas those receiving aripiprazole lost a mean of 0.9 kg. aripiprazole lost a mean of 0.9 kg.
The final set of prospective data comes The final set of prospective data comes from a 12-month RCT in which 160 from a 12-month RCT in which 160 patients in China with first-episode schizopatients in China with first-episode schizophrenia were randomised to treatment with phrenia were randomised to treatment with clozapine or chlorpromazine (Lieberman clozapine or chlorpromazine (Lieberman et et al al, 2003) . Fasting blood glucose levels were , 2003). Fasting blood glucose levels were tested at 3-month intervals after baseline tested at 3-month intervals after baseline assessment. No treatment difference was assessment. No treatment difference was seen between the patient groups, and no seen between the patient groups, and no incident case of diabetes was reported. incident case of diabetes was reported. Initial fasting blood glucose levels of Initial fasting blood glucose levels of 4.8 mmol/l in the chlorpromazine cohort 4.8 mmol/l in the chlorpromazine cohort and 4.7 mmol/l in the clozapine cohort rose and 4.7 mmol/l in the clozapine cohort rose slightly by 12 weeks to 4.9 mmol/l and slightly by 12 weeks to 4.9 mmol/l and 5.1 mmol/l, respectively. At 52 weeks, there 5.1 mmol/l, respectively. At 52 weeks, there was no between-group difference, with fastwas no between-group difference, with fasting blood ing blood glucose levels of 5.5 mmol/l and glucose levels of 5.5 mmol/l and 5.3 mmol/l, 5.3 mmol/l, respectively (95% CI respectively (95% CI À0.32 to 0.32 to 0.67; 0.67; P P¼0.49). 0.49). Whatever the mechanism behind the Whatever the mechanism behind the emergence of diabetes in patients with emergence of diabetes in patients with schizophrenia, clearly no single risk factor schizophrenia, clearly no single risk factor is solely responsible. Although the number is solely responsible. Although the number of individual risk factors present at baseline of individual risk factors present at baseline was shown to be an independent risk factor was shown to be an independent risk factor for treatment-emergent diabetes, the prefor treatment-emergent diabetes, the presence of weight gain (defined as an increase sence of weight gain (defined as an increase of at least 7% in body weight) during the of at least 7% in body weight) during the trials was not found to be an independent trials was not found to be an independent risk factor for diabetes development risk factor for diabetes development (Sowell (Sowell et al et al, 2003) . , 2003) . Hyperprolactinaemia may also lead to Hyperprolactinaemia may also lead to insulin resistance, and this is seen to a insulin resistance, and this is seen to a greater extent in patients taking risperidone greater extent in patients taking risperidone than in those treated with conventional than in those treated with conventional antipsychotics (David antipsychotics (David et al et al, 2000; Kinon , 2000; Kinon et al et al, 2003) . In a point prevalence study, , 2003) . In a point prevalence study, Kinon Kinon et al et al (2003) found that the (2003) 50.001) . Nevertheless, even when 0.001). Nevertheless, even when allowing for the spectra of antipsychoticallowing for the spectra of antipsychoticassociated weight gain (higher with olanzaassociated weight gain (higher with olanzapine and clozapine, lower with aripiprazole pine and clozapine, lower with aripiprazole and quetiapine) seen with all atypical antiand quetiapine) seen with all atypical antipsychotics, other than maybe ziprasidone psychotics, other than maybe ziprasidone (Taylor & McAskill, 2000; Taylor (Taylor & McAskill, 2000; Taylor et al et al, , 2003) , and hyperprolactinaemia (higher 2003), and hyperprolactinaemia (higher with risperidone and amisulpride, lower with risperidone and amisulpride, lower with olanzapine and quetiapine), it is diffiwith olanzapine and quetiapine), it is difficult to propose a unifying mechanism to cult to propose a unifying mechanism to explain why patients with schizophrenia explain why patients with schizophrenia might develop diabetes. Certainly, factors might develop diabetes. Certainly, factors associated with schizophrenia itself probassociated with schizophrenia itself probably account for many cases. ably account for many cases.
Prospective data from treatment-naıve Prospective data from treatment-naïve patients with first-episode schizophrenia patients with first-episode schizophrenia suggest that glycaemic abnormalities might suggest that glycaemic abnormalities might be present prior to the initiation of any be present prior to the initiation of any antipsychotic treatment (Ryan antipsychotic treatment (Ryan et al et al, , 2003) . In a study of 26 patients with 2003). In a study of 26 patients with schizophrenia, 4 patients (15%) were found schizophrenia, 4 patients (15%) were found to have impaired glucose tolerance, in conto have impaired glucose tolerance, in contrast to no patient in the control group trast to no patient in the control group (Ryan (Ryan et al et al, 2003) . The additional finding , 2003). The additional finding of raised cortisol levels and insulin resisof raised cortisol levels and insulin resistance in the treatment-naıve patients, comtance in the treatment-naïve patients, combined with data from the same group bined with data from the same group showing that they had 3.4 times as much showing that they had 3.4 times as much visceral fat as the control group, lends visceral fat as the control group, lends support to the hypothesis that schizosupport to the hypothesis that schizophrenia itself might lead to raised cortisol phrenia itself might lead to raised cortisol levels and insulin resistance and this, in levels and insulin resistance and this, in turn, might lead to the metabolic syndrome turn, might lead to the metabolic syndrome (Ryan & Thakore, 2002) . (Ryan & Thakore, 2002) . s 9 0 s 9 0 Table 2  Table 2 Summary of prospective randomised controlled trials with antipsychotic drug comparators:
Summary of prospective randomised controlled trials with antipsychotic drug comparators: In summary, in all the prospective In summary, in all the prospective RCTs and prospective cohort studies RCTs and prospective cohort studies conducted to date, no difference has been conducted to date, no difference has been reported between the antipsychotic reported between the antipsychotic medications in terms of their association medications in terms of their association with glucose abnormalities. The evaluation with glucose abnormalities. The evaluation and comparison between different antiand comparison between different antipsychotics of numbers of incident cases of psychotics of numbers of incident cases of diabetes proves difficult owing to the diabetes proves difficult owing to the small numbers of such incident cases. A small numbers of such incident cases. A lack of demographic data also hinders lack of demographic data also hinders any extrapolation to the wider general any extrapolation to the wider general population of patients with schizophrenia. population of patients with schizophrenia.
Prospective case series Prospective case series
Three case reports or series can be found in Three case reports or series can be found in the literature involving patients with the literature involving patients with diabetes who have started treatment with diabetes who have started treatment with atypical antipsychotic medications. Yu atypical antipsychotic medications. Yu et al et al (2002) described 22 patients known (2002) described 22 patients known to have diabetes in whom no worsening of to have diabetes in whom no worsening of diabetic control was seen after antidiabetic control was seen after antipsychotic treatment was begun. Indeed, in psychotic treatment was begun. Indeed, in 4 of the 11 patients prescribed olanzapine, 4 of the 11 patients prescribed olanzapine, improvements in glucose control were seen; improvements in glucose control were seen; one patient was switched from insulin to one patient was switched from insulin to oral hypoglycaemic therapy. Lindenmayer oral hypoglycaemic therapy. Lindenmayer et al et al (2003) reported that in their cohort, (2003) reported that in their cohort, 5 out of 7 patients known to have diabetes 5 out of 7 patients known to have diabetes showed improved glucose control after showed improved glucose control after beginning treatment with atypical antibeginning treatment with atypical antipsychotic medications. Green (2003) psychotic medications. Green (2003) described a female patient who, by improvdescribed a female patient who, by improving her mental health with olanzapine, was ing her mental health with olanzapine, was able to improve her glucose control. able to improve her glucose control.
DISCUSSION DISCUSSION
Currently available prospective clinical Currently available prospective clinical data assessing glucose control in patients data assessing glucose control in patients with schizophrenia being treated with antiwith schizophrenia being treated with antipsychotic medications does not support any psychotic medications does not support any difference in diabetogenic potential bedifference in diabetogenic potential between the atypical antipsychotic drugs that tween the atypical antipsychotic drugs that have been studied. Indeed, where placebo have been studied. Indeed, where placebo data have been available, no difference in data have been available, no difference in the rates of emergence of glucose abnorthe rates of emergence of glucose abnormalities has been seen between placebo malities has been seen between placebo cohorts and cohorts receiving active drug cohorts and cohorts receiving active drug comparators. comparators.
The prospective data available to date The prospective data available to date suggest that the diabetogenic potential presuggest that the diabetogenic potential previously ascribed to atypical antipsychotic viously ascribed to atypical antipsychotic drugs as a result of retrospective studies drugs as a result of retrospective studies may be incorrect. Blood glucose data from may be incorrect. Blood glucose data from placebo groups indicate that type 2 diabetes placebo groups indicate that type 2 diabetes is a progressive illness, and that a natural is a progressive illness, and that a natural vulnerability to diabetes in patients with vulnerability to diabetes in patients with schizophrenia (when combined with other schizophrenia (when combined with other lifestyle factors) may be enough to trigger lifestyle factors) may be enough to trigger glucose abnormalities in these individuals. glucose abnormalities in these individuals.
In all studies where comparative proIn all studies where comparative prospective data are available, no difference spective data are available, no difference has been found in the incidence rates of has been found in the incidence rates of type 2 diabetes over follow-up periods that type 2 diabetes over follow-up periods that have extended up to 1 year. Such data are have extended up to 1 year. Such data are currently available for all atypical anticurrently available for all atypical antipsychotic medications except quetiapine psychotic medications except quetiapine and amisulpride. and amisulpride.
No conclusion can currently be drawn No conclusion can currently be drawn regarding the incidence of diabetes in regarding the incidence of diabetes in patients with schizophrenia. The incidence patients with schizophrenia. The incidence rates for new cases over a 6-month period rates for new cases over a 6-month period are likely to be around 0.8%, as seen for are likely to be around 0.8%, as seen for aripiprazole and olanzapine (Food and Drug aripiprazole and olanzapine (Food and Drug Administration, 2003 A number of problems in the interpret-A number of problems in the interpretation of blood glucose assessment data ation of blood glucose assessment data from studies of schizophrenia remain. from studies of schizophrenia remain. There are clearly difficulties in obtaining There are clearly difficulties in obtaining fasting blood glucose samples from people fasting blood glucose samples from people with mental health problems. Consewith mental health problems. Consequently, most studies to date have used quently, most studies to date have used random blood glucose measurements, random blood glucose measurements, which are less reliable predictors of diawhich are less reliable predictors of diabetes. Some studies have not yet reported betes. Some studies have not yet reported their data in full, and some have used their data in full, and some have used definitions of glycaemic abnormalities that definitions of glycaemic abnormalities that do not conform to the diagnostic guidelines do not conform to the diagnostic guidelines of international bodies such as the Ameriof international bodies such as the American Diabetes Association (1997) and the can Diabetes Association (1997) and the World Health Organization (1999). The World Health Organization (1999) . The data discussed do not always appear to data discussed do not always appear to represent the full cohort of patients who represent the full cohort of patients who participated in the relevant clinical trial. participated in the relevant clinical trial. Selection bias cannot be excluded as a cause Selection bias cannot be excluded as a cause for an individual study's results. for an individual study's results.
The significance of impaired glucose The significance of impaired glucose tolerance in schizophrenia needs to be fully tolerance in schizophrenia needs to be fully determined within a physical health framedetermined within a physical health framework that would allow patients with work that would allow patients with schizophrenia who have this abnormality schizophrenia who have this abnormality to receive all necessary treatment and to receive all necessary treatment and advice. Diabetologists have talked about advice. Diabetologists have talked about undertaking diabetes prevention studies, undertaking diabetes prevention studies, and the high risk of diabetes and impaired and the high risk of diabetes and impaired glucose tolerance in patients with schizoglucose tolerance in patients with schizophrenia would make them an ideal study phrenia would make them an ideal study population. population.
There remains a pressing need for There remains a pressing need for adequate, longitudinal, prospective, comadequate, longitudinal, prospective, comparative data from patients treated with parative data from patients treated with atypical antipsychotic drugs. Whether atypical antipsychotic drugs. Whether further data are required for the convenfurther data are required for the conventional antipsychotic agents is a matter for tional antipsychotic agents is a matter for debate. Current recommendations from debate. Current recommendations from the National Institute for Clinical Excelthe National Institute for Clinical Excellence (2002) in the UK make it clear that lence (2002) in the UK make it clear that all new patients and most existing patients all new patients and most existing patients with schizophrenia should preferably rewith schizophrenia should preferably receive atypical antipsychotic medication. ceive atypical antipsychotic medication.
The available prospective data do not The available prospective data do not help to clarify the possibility that the help to clarify the possibility that the diabetogenic potential of atypical antidiabetogenic potential of atypical antipsychotic medications may be greater than psychotic medications may be greater than for conventional agents. Any future studies for conventional agents. Any future studies will need to consider carefully the options will need to consider carefully the options for random blood glucose measurements for random blood glucose measurements as opposed to traditional fasting blood as opposed to traditional fasting blood glucose testing. Clear guidelines will also glucose testing. Clear guidelines will also be required for appropriate glucose monibe required for appropriate glucose monitoring in patients with schizophrenia, both toring in patients with schizophrenia, both with and without medication. Such guidewith and without medication. Such guidelines should include recommendations lines should include recommendations about which glucose tests should be about which glucose tests should be performed and how often they should be performed and how often they should be undertaken. undertaken.
There is little doubt that greater awareThere is little doubt that greater awareness of the risk of diabetes and impaired ness of the risk of diabetes and impaired glucose tolerance associated with schizoglucose tolerance associated with schizophrenia will increase the workload of many phrenia will increase the workload of many health care services. Decisions need to be health care services. Decisions need to be made about when and where the future made about when and where the future diagnosis and management of glycaemic diagnosis and management of glycaemic abnormalities should occur, and who abnormalities should occur, and who should assume responsibility for providing should assume responsibility for providing these services. Further and fuller guidance these services. Further and fuller guidance (and possibly funding) for these services (and possibly funding) for these services may be required. may be required. Alberti, K. G. (1996) Alberti, K. G. (1996) It is difficult to obtain fasting plasma glucose levels in people with a serious mental illness such as schizophrenia, and therefore difficult to confidently categorise glucose illness such as schizophrenia, and therefore difficult to confidently categorise glucose abnormalities.The glucose tests used and the definitions of abnormality differ abnormalities.The glucose tests used and the definitions of abnormality differ between studies. between studies.
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